Phone: 203 796 5000
Fax: 203 796 5002
Website: http://www.biodel.com

Contact(s)
Solomon S. Steiner, PhD - Founder & CS - [email protected]

General Information
Biodel Inc. is a specialty biopharmaceutical company focused on the development and commercialization of innovative treatments for diabetes. Biodel's product candidates are developed using VIAdel(TM) technology, which reformulates existing FDA-approved peptide drugs.

Research Activities
Biodel's new drug application for its most advanced product candidate, VIAject(R), has been accepted for review by the U.S. Food and Drug Administration with a Prescription Drug User Fee Act action date of October 30, 2010. Earlier stage product candidates include VIAtab(R), a sublingual tablet formulation of insulin, a line of adjustable basal insulins, a "smart" basal insulin and a stabilized formula of glucagon.

Other Information
Ownership: public
Stock Symbol: BIOD
CT Employees: 56
World Employees: 56

Back